Oncobiologics, inVentiv Health Inc. deal
CRO inVentiv Health will provide clinical and bioanalytical support worldwide for the development of Oncobiologics' pipeline of preclinical biosimilars. The biosimilars include autoimmune drug Humira adalimumab; autoimmune and cancer drug Rituxan rituximab; and cancer drugs Avastin bevacizumab, Herceptin trastuzumab and Eribtux cetuximab. Oncobiologics said it has an option to offer inVentiv commercialization rights to the biosimilars in countries where Oncobiologics retains commercialization rights. However, Oncobiologics said its primary strategy is to offer commercialization rights to pharmas or biotechs that can support clinical development of the products and have their own commercialization structure. Oncobiologics said the deal also may be expanded to include the development of Oncobiologics' innovative molecules in discovery, which include ONS-1015, ONS-2010 and ONS-3015. Oncobiologics is developing ONS-1015 for lung, breast and head and neck cancer; ONS-2010 for renal cancer and melanoma; and ONS-3015 for rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis and psoriasis. Oncobiologics and inVentiv declined to disclose details on the deal. ...